Breast Cancer Treatment Insurance Denied? How to Appeal

A breast cancer diagnosis is already one of the most difficult things a person can face. Receiving an insurance denial on top of it — for trastuzumab, hormonal therapy, CDK4/6 inhibitors, a reconstruction procedure, or any other treatment your oncologist has recommended — makes an overwhelming situation worse. Denials in this category are rarely the final word. When appeals are backed by strong clinical documentation and the correct legal arguments, breast cancer treatment denials are reversed at meaningful rates. Time matters: expedited appeal rights exist precisely for situations like yours.

Why Insurers Deny Breast Cancer Treatment

"Not medically necessary" for standard-of-care treatment. The insurer claims the treatment does not meet its internal clinical criteria, even when your oncologist has determined it is the appropriate standard of care for your specific tumor type, stage, and molecular profile. NCCN Clinical Practice Guidelines in Oncology — Breast Cancer provide category-level recommendations (Category 1, 2A, 2B) that are the recognized clinical standard in insurance coverage disputes.

Off-label use denials. Drugs including trastuzumab (Herceptin), pertuzumab (Perjeta), sacituzumab govitecan (Trodelvy), and CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) may be denied for your specific subtype or disease stage on the grounds of "off-label" use — even when NCCN Category 1 or 2A guidelines support them for your indication. Most states have enacted off-label cancer drug mandates requiring coverage when supported by recognized compendia including NCCN, DrugDex, or AHFSDi.

Step therapy requirements. Insurers mandate a trial of hormonal therapies before approving targeted agents for HR+/HER2- disease, or sequence other agents before CDK4/6 inhibitors, even when the cancer's molecular profile and clinical presentation make that sequencing inappropriate. ICD-10 codes documenting tumor subtype — C50.911 through C50.929 for primary breast cancer by site, with molecular subtype documented in the pathology report — support the clinical justification for bypassing step therapy.

Reconstruction and WHCRA violations. Under the Women's Health and Cancer Rights Act of 1998 (WHCRA, 29 U.S.C. §1185b), health plans that cover mastectomy must also cover reconstruction of the breast on which the mastectomy was performed, surgery and reconstruction of the other breast to produce a symmetrical appearance, and prostheses and treatment of physical complications. Denial of reconstruction or contralateral prophylactic mastectomy in BRCA1/2 mutation carriers is frequently challenged and overturned.

Experimental treatment exclusions. PARP inhibitors (olaparib, niraparib, talazoparib) for BRCA-mutated breast cancer and immunotherapy combinations for triple-negative breast cancer carry FDA approval for specific indications. Denial of FDA-approved therapies as "investigational" is a specific, arguable position that can be countered with the FDA approval letter, NCCN guidelines, and peer-reviewed literature.

How to Appeal a Breast Cancer Treatment Denial

Step 1: Obtain the Full Denial and the Insurer's Coverage Criteria

Request your formal denial letter, EOB)" class="auto-link">Explanation of Benefits (EOB), and a copy of the insurer's clinical coverage policy for the specific drug or procedure denied. The coverage policy reveals exactly what clinical criteria the plan applied. Compare these criteria against the current-year NCCN Breast Cancer guidelines (available at nccn.org with free registration) to identify specific points of contradiction.

Step 2: Get Your Oncologist's Letter of Medical Necessity Immediately

Your oncologist's letter is the single most important document in a cancer treatment appeal. It must include your ICD-10 diagnosis code (C50.x for primary breast cancer, with documentation of stage and molecular subtype in the pathology report), your molecular subtype (HR+/HER2-, HER2+, triple-negative, BRCA1/2 mutation status), an explanation of why the requested treatment is the appropriate standard of care, a specific NCCN guideline citation with category level, and a direct response to the insurer's stated denial reason.

Step 3: Request a Peer-to-Peer Review Within Five Days

Ask your oncologist to call the insurer's medical director for a peer-to-peer review. This physician-to-physician conversation resolves many breast cancer denials before a formal written appeal is required. It is most effective within the first five days of receiving the denial, before the insurer's position becomes entrenched. Document the date, time, and outcome of the peer-to-peer call in writing to your insurer.

Step 4: File the Internal Appeal Addressing Every Denial Criterion

Submit a written appeal that responds specifically to every stated denial reason. For off-label denials, cite the NCCN category recommendation and attach the relevant guideline table. Include your state's off-label cancer drug mandate citation — most states require coverage of off-label cancer drugs supported by NCCN, DrugDex, or other standard compendia. For WHCRA reconstruction denials, cite the statute (29 U.S.C. §1185b) and the plan's acknowledgment of the WHCRA notice obligation that must be provided at enrollment.

Step 5: Request Expedited Review if Treatment Is Time-Sensitive

If treatment delay would seriously jeopardize your health, request an expedited internal appeal. Under federal regulations (29 CFR §2560.503-1), plans must decide expedited appeals within 72 hours of receipt. Your oncologist's attestation that delayed treatment creates serious risk is sufficient to trigger expedited processing. Document your request in writing.

Step 6: Escalate to External Independent Review: Complete Guide" class="auto-link">External Review and Regulatory Complaints

If the internal appeal is denied, file for independent external review immediately — do not wait. For state-regulated plans, file through your state insurance commissioner. For ERISA employer plans, the federal external review process applies. External reviewers with oncology expertise assess your case against clinical standards rather than the insurer's internal criteria. Simultaneously, file a complaint with your state insurance commissioner (or DOL EBSA at 1-866-444-3272 for ERISA plans) and your state attorney general if WHCRA or off-label mandates were violated.

What to Include in Your Appeal

• Oncologist's letter of medical necessity with ICD-10 code, molecular subtype documentation, NCCN guideline citation with category level, and specific response to the denial reason
• Pathology report documenting tumor stage, receptor status (ER, PR, HER2), and any genomic testing results (Oncotype DX, FoundationOne CDx, BRCA germline testing)
• NCCN guideline excerpt showing the specific recommendation for your tumor subtype and disease stage
• WHCRA notice acknowledgment and statute citation for reconstruction denials, or off-label state mandate citation for drug denials

Fight Back With ClaimBack

A breast cancer treatment denial is an administrative decision — not a medical opinion — and it can be challenged with the clinical evidence your oncologist has already assembled. NCCN guidelines, the Women's Health and Cancer Rights Act, and federal and state appeal rights are powerful tools. ClaimBack generates a professional, oncology-specific appeal letter in 3 minutes, so you can focus on treatment rather than paperwork.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal